Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Penn study suggests a new type of pain reliever that may benefit the heart
Furthermore, the composition of the animals’ blood vessels showed that the disease process had not only slowed, but also stabilized. This study points to the possibility of a
Furthermore, the composition of the animals’ blood vessels showed that the disease process had not only slowed, but also stabilized. This study points to the possibility of a
The findings are also encouraging, the researchers say, because they demonstrate the ability to create a vaccine based on one particular strain of the H5N1 flu virus that
Pharmacopeia said that the progress of the compound validated the company’s strategy of finding partners to help with the development of its internal therapeutic candidates. Pharmacopeia will receive
The FDA approved the use of Plavix, which Bristol-Myers Squibb produces in partnership with Sanofi-Aventis, to reduce the risk of death from any cause and the risk of
The settlement covers the dispute for the period 1989-2000, which was due to go to trial in February 2007, and also covers the subsequent years 2001-2005. GSK said
Antisoma says that the new data highlights the key role of white blood cells called natural killer (NK) cells in the action of the drug. A team from
Oncologic Drugs Advisory Committee (ODAC) panel members recommended that Abraxis and the FDA work together to identify selected patient populations for a “reasonably sized” randomized trial to confirm
The deal, worth $2.5 billion, “represents a superior business proposition which will best ensure the future development and growth of the combined company in all markets, including Croatia
Under the terms of the agreement Medivir will receive equity in Epiphany, milestone payments of maximally $24.5 million and royalties from world wide sales except the Nordic countries
Through the deal Eisai, known for its Alzheimer treatment drug Aricept, will acquire the exclusive global rights for Ontak, which is FDA-approved to treat persistent or recurrent cutaneous